Asset
PAMREVLUMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01181245 | phase1 | completed | 2008-12-01 | 2014-05-01 | Kyntra Bio | A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer |
| NCT01217632 | phase2 | terminated | 2010-08-01 | 2015-06-01 | Kyntra Bio | A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection |
| NCT02210559 | phase1_2 | completed | 2014-07-31 | 2021-12-15 | Kyntra Bio | A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer |
| NCT01890265 | phase2 | completed | 2013-07-30 | 2017-11-16 | Kyntra Bio | Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
| NCT03941093 | phase3 | completed | 2019-05-10 | 2024-06-11 | Kyntra Bio | Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer |
FDA applications (0)
This company has no applications containing this asset.